Unexplained recurrent endometrial cavity fluid
Conditions
Interventions
Trial Group:Intrauterine infusion of dexamethasone injection (dose: 5mg dissolved in 1mL sterile saline) once daily for 3 consecutive days during the secretory phase
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Age 20-40 2. At least two independent cycles confirmed by transvaginal ultrasound to have unexplained recurrent endometrial cavity fluid (APD = 3.5mm)
Exclusion criteria
Exclusion criteria: 1. allergic to dexamethasone; 2. active genital tract or systemic infection; 3. contraindications to the use of glucocorticoids such as uncontrolled diabetes and hypertension; 4. endometrial lesions (such as polyps and multiple myomas) requiring surgery; 5. known causes such as oviduct effusion, uterine scar diverticulum and uterine malformation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute and relative change rate of maximum anteroposterior diameter (APD) of uterine cavity fluid;Safety outcomes (including incidence and severity of treatment-related adverse events, post-infusion abdominal pain and bleeding symptoms, signs of infection, and hormone-related side effects); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Embryo implantation rate;Endometrial SCNN1A expression level; | — |
Countries
China
Contacts
Public ContactLi Rong
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital
Outcome results
None listed